SCHEMBL20374413

SCHEMBL20374413

CCOC(=O)c1ccc(-c2noc(-c3cnc4cc(Cl)ccc4c3)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ MAPT P10636 6/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ GLA P06280 1/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ TSHR P16473 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MAOB P27338 2/20 0.47
▸ SIRT2 Q8IXJ6 1/20 0.46
▸ SIRT1 Q96EB6 1/20 0.46
▸ SIRT3 Q9NTG7 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.44
▸ HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20362087 0.89 PDGFRB (0.54) PDGFRBPDGFRAMAPTMEN1LMNA
SCHEMBL20362094 0.83 PDGFRB (0.48) PDGFRBPDGFRAMAPTMEN1LMNA
SCHEMBL2204650 0.80 MAOB (0.65) PDGFRBPDGFRAMAPTMEN1KMT2A
SCHEMBL26092553 0.74 MAPT (0.49) MAPTMEN1LMNAMAPK1KMT2A
SCHEMBL3230760 0.73 HTT (0.68) MAPTMEN1LMNAMAPK1KMT2A
SCHEMBL7195236 0.72 ACHE (0.51) MAPTMEN1LMNAMAPK1KMT2A
SCHEMBL8500962 0.72 PDGFRB (0.62) PDGFRBPDGFRAMEN1KMT2ASMN1; SMN2
SCHEMBL12171483 0.71 MAPT (0.67) MAPTMEN1LMNAMAPK1KMT2A
SCHEMBL11561855 0.71 LMNA (0.59) MAPTMEN1LMNAMAPK1KMT2A
SCHEMBL10465995 0.71 MAOB (0.65) PDGFRBPDGFRAMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3565807-B1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL MED MOUNT SINAI (US) 2021-09-22 — — EP disclosed
US-10669266-B2 Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-06-02 — — US disclosed
US-20190352292-A1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2019-11-21 — — US disclosed
WO-2018129274-A1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2018-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352292-A1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS HIPK2, HIPK3, HIPK1 PDGFRB 883/4885PDGFRA 1704/4885MAPT 3945/4885
US-10669266-B2 Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis HIPK2, HIPK3, HIPK1 PDGFRB 883/4885PDGFRA 1704/4885MAPT 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback